Novel Unbiased Equations to Calculate Triglyceride-rich Lipoprotein Cholesterol from Routine Non-fasting Lipids

Overview

Journal Cardiovasc Diabetol

Publisher Biomed Central

Specialties Cardiology & Vascular Diseases
Endocrinology

Date 2014 Mar 12

PMID 24612479

Citations 7

Authors

Michel P Hermans

Sylvie A Ahn

Michel F Rousseau

Affiliations

Soon will be listed here.

Abstract

Background: Non-fasting triglyceride-rich lipoproteins cholesterol (TRL-C) contributes to cardiovascular risk, in that it includes remnant cholesterol (RC). TRL-C is computed as total C - [LDL-C + HDL-C]. Such calculation applies only if LDL-C is directly measured, or obtained from a non-Friedewald's formula, a method as yet never benchmarked against independent markers of TRL burden.

Methods: The Discriminant Ratio (DR) methodology was used in 120 type 2 diabetic patients in order: (i) to compute TRL-C from non-fasting lipids; (ii) to establish the performance of TRL-C and TRL-C/apoA-I (vs. TG-based markers) to grade TRLs and atherogenic dyslipidemia (AD); and (iii) to relate TRL-C with non-fasting TG.

Results: Depending on apoB100 availability, TRL-C (mg/dL) can be derived from non-fasting lipids in two ways: (a) total cholesterol (TC) - [(0.0106 * TC - 0.0036 * TG + 0.017 * apoB100 - 0.27) * 38.6] - HDL-C; and (b) TC - [(0.0106 * TC - 0.0036 * TG + 0.017 * [0.65 * (TC - HDL-C) + 6.3] - 0.27) * 38.6] - HDL-C. Discrimination between log[TG] and TRL-C was similar (DR 0.94 and 0.84, respectively), whereas that of log[TG]/HDL-C was better than TRL-C/apoA-I (DR 1.01 vs. 0.65; p 0.0482). All Pearson's correlations between pairs reached unity, allowing formulation of two unbiased equivalence equations: (a) TRL-C = 97.8 * log[TG] - 181.9; and (b) TRL-C/apoA-I = 8.15 * (log[TG]/HDL-C) - 0.18.

Conclusions: TRL-C and log[TG] are as effective and interchangeable for assessing remnant atherogenic particles. For grading TRL-AD, it is best to use log[TG]/HDL-C, inherently superior to TRL-C/apoA-I, while measuring the same underlying variable.

Citing Articles

Validation of Friedewald, Martin-Hopkins and Sampson low-density lipoprotein cholesterol equations.

Zararsiz G, Bolat S, Cephe A, Kochan N, Yerlitas S, Dogan H PLoS One. 2022; 17(5):e0263860.

PMID: 35559957 PMC: 9106156. DOI: 10.1371/journal.pone.0263860.

Apolipoprotein B and Cardiovascular Disease: Biomarker and Potential Therapeutic Target.

Behbodikhah J, Ahmed S, Elyasi A, Kasselman L, Leon J, Glass A Metabolites. 2021; 11(10).

PMID: 34677405 PMC: 8540246. DOI: 10.3390/metabo11100690.

Comparison of calculated remnant lipoprotein cholesterol levels with levels directly measured by nuclear magnetic resonance.

Chen J, Kuang J, Tang X, Mao L, Guo X, Luo Q Lipids Health Dis. 2020; 19(1):132.

PMID: 32522276 PMC: 7285517. DOI: 10.1186/s12944-020-01311-w.

Recombinant Incretin-Secreting Microbe Improves Metabolic Dysfunction in High-Fat Diet Fed Rodents.

Ryan P, Patterson E, Kent R, Stack H, OConnor P, Murphy K Sci Rep. 2017; 7(1):13523.

PMID: 29051554 PMC: 5648875. DOI: 10.1038/s41598-017-14010-x.

Changes in triglycerides and high-density lipoprotein cholesterol may precede peripheral insulin resistance, with 2-h insulin partially mediating this unidirectional relationship: a prospective cohort study.

Han T, Cheng Y, Tian S, Wang L, Liang X, Duan W Cardiovasc Diabetol. 2016; 15(1):154.

PMID: 27814764 PMC: 5095985. DOI: 10.1186/s12933-016-0469-3.

References

Sarwar N, Sandhu M, Ricketts S, Butterworth A, Di Angelantonio E, Boekholdt S . Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet. 2010; 375(9726):1634-9. PMC: 2867029. DOI: 10.1016/S0140-6736(10)60545-4. View

Martin S, Blaha M, Elshazly M, Brinton E, Toth P, McEvoy J . Friedewald-estimated versus directly measured low-density lipoprotein cholesterol and treatment implications. J Am Coll Cardiol. 2013; 62(8):732-9. DOI: 10.1016/j.jacc.2013.01.079. View

Querton L, Buysschaert M, Hermans M . Hypertriglyceridemia and residual dyslipidemia in statin-treated, patients with diabetes at the highest risk for cardiovascular disease and achieving very-low low-density lipoprotein-cholesterol levels. J Clin Lipidol. 2012; 6(5):434-42. DOI: 10.1016/j.jacl.2012.04.002. View

Bairaktari E, Hatzidimou K, Tzallas C, Vini M, Katsaraki A, Tselepis A . Estimation of LDL cholesterol based on the Friedewald formula and on apo B levels. Clin Biochem. 2000; 33(7):549-55. DOI: 10.1016/s0009-9120(00)00162-4. View

Bjorkegren J, Karpe F, Milne R, Hamsten A . Differences in apolipoprotein and lipid composition between human chylomicron remnants and very low density lipoproteins isolated from fasting and postprandial plasma. J Lipid Res. 1998; 39(7):1412-20. View

Kothari V, Stevens R, Adler A, Stratton I, Manley S, Andrew Neil H . UKPDS 60: risk of stroke in type 2 diabetes estimated by the UK Prospective Diabetes Study risk engine. Stroke. 2002; 33(7):1776-81. DOI: 10.1161/01.str.0000020091.07144.c7. View

Varbo A, Benn M, Tybjaerg-Hansen A, Jorgensen A, Frikke-Schmidt R, Nordestgaard B . Remnant cholesterol as a causal risk factor for ischemic heart disease. J Am Coll Cardiol. 2012; 61(4):427-436. DOI: 10.1016/j.jacc.2012.08.1026. View

Hermans M, Ahn S, Rousseau M . log(TG)/HDL-C is related to both residual cardiometabolic risk and β-cell function loss in type 2 diabetes males. Cardiovasc Diabetol. 2010; 9:88. PMC: 3020173. DOI: 10.1186/1475-2840-9-88. View

Kannel W, Vasan R . Triglycerides as vascular risk factors: new epidemiologic insights. Curr Opin Cardiol. 2009; 24(4):345-50. PMC: 3012388. DOI: 10.1097/HCO.0b013e32832c1284. View

10.

Hermans M, Sacks F, Ahn S, Rousseau M . Non-HDL-cholesterol as valid surrogate to apolipoprotein B100 measurement in diabetes: Discriminant Ratio and unbiased equivalence. Cardiovasc Diabetol. 2011; 10:20. PMC: 3056766. DOI: 10.1186/1475-2840-10-20. View

11.

Fruchart J, Sacks F, Hermans M . Implications of the ACCORD lipid study: perspective from the Residual Risk Reduction Initiative (R(3)i). Curr Med Res Opin. 2010; 26(8):1793-7. DOI: 10.1185/03007995.2010.489341. View

12.

Jacobson T . Opening a new lipid "apo-thecary": incorporating apolipoproteins as potential risk factors and treatment targets to reduce cardiovascular risk. Mayo Clin Proc. 2011; 86(8):762-80. PMC: 3146376. DOI: 10.4065/mcp.2011.0128. View

13.

Levey A, Bosch J, Lewis J, Greene T, Rogers N, Roth D . A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999; 130(6):461-70. DOI: 10.7326/0003-4819-130-6-199903160-00002. View

14.

Alberti K, Eckel R, Grundy S, Zimmet P, Cleeman J, Donato K . Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation;.... Circulation. 2009; 120(16):1640-5. DOI: 10.1161/CIRCULATIONAHA.109.192644. View

15.

Murase T, Okubo M, Takeuchi I . Non-HDL-cholesterol/apolipoprotein B ratio: a useful distinguishing feature in the screening for type III hyperlipoproteinemia. J Clin Lipidol. 2010; 4(2):99-104. DOI: 10.1016/j.jacl.2010.01.004. View

16.

Fruchart J, Davignon J, Hermans M, Al-Rubeaan K, Amarenco P, Assmann G . Residual macrovascular risk in 2013: what have we learned?. Cardiovasc Diabetol. 2014; 13:26. PMC: 3922777. DOI: 10.1186/1475-2840-13-26. View

17.

Hermans M, Ahn S, Rousseau M . The atherogenic dyslipidemia ratio [log(TG)/HDL-C] is associated with residual vascular risk, beta-cell function loss and microangiopathy in type 2 diabetes females. Lipids Health Dis. 2012; 11:132. PMC: 3539971. DOI: 10.1186/1476-511X-11-132. View

18.

Hermans M, Ahn S, Rousseau M . The multi-faceted outcomes of conjunct diabetes and cardiovascular familial history in type 2 diabetes. J Diabetes Complications. 2012; 26(3):187-94. DOI: 10.1016/j.jdiacomp.2012.03.014. View

19.

Fujioka Y, Ishikawa Y . Remnant lipoproteins as strong key particles to atherogenesis. J Atheroscler Thromb. 2009; 16(3):145-54. DOI: 10.5551/jat.e598. View

20.

Langsted A, Freiberg J, Tybjaerg-Hansen A, Schnohr P, Jensen G, Nordestgaard B . Nonfasting cholesterol and triglycerides and association with risk of myocardial infarction and total mortality: the Copenhagen City Heart Study with 31 years of follow-up. J Intern Med. 2011; 270(1):65-75. DOI: 10.1111/j.1365-2796.2010.02333.x. View